All Issue

2024 Vol.54, Issue 1

Review Article

31 March 2024. pp. 1-11
Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol 2010;1:134. 10.3389/fmicb.2010.0013421687759PMC3109405
Rahman MS, Koh YS. Omadacycline, a magic antibiotics for bacterial infections. J Bacteriol Virol 2018;48:109-12. 10.4167/jbv.2018.48.3.109
Nelson ML, Levy SB. The history of the tetracyclines. Ann N Y Acad Sci 2011;1241:17-32. 10.1111/j.1749-6632.2011.06354.x22191524
Bassett EJ, Keith MS, Armelagos GJ, Martin DL, Villanueva AR. Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350). Science 1980;209:1532-4. 10.1126/science.70016237001623
Heaney M, Mahoney MV, Gallagher JC. Eravacycline: the tetracyclines strike back. Ann Pharmacother 2019;53: 1124-35. 10.1177/106002801985017331081341
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs 2016;76:567-88. 10.1007/s40265-016-0545-826863149
Terreni M, Taccani M, Pregnolato M. New antibiotics for multidrug-resistant bacterial strains: latest research developments and future perspectives. Molecules 2021;26:2671. 10.3390/molecules2609267134063264PMC8125338
Monogue ML, Thabit AK, Hamada Y, Nicolau DP. Antibacterial efficacy of eravacycline in vivo against gram-positive and gram-negative organisms. Antimicrob Agents Chemother 2016;60:5001-5. 10.1128/AAC.00366-1627353265PMC4958151
Rahman MS, Koh YS. A novel antibiotic agent, cefiderocol, for multidrug-resistant Gram-negative bacteria. J Bacteriol Virol 2020;50:218-26. 10.4167/jbv.2020.50.4.218
Rahman MS, Al Amin GM, Anwar SM, Azam MF, Akhter F, Islam MR, et al. Plazomicin-a new aminoglycoside-for treating complicated urinary tract infections. J Bacteriol Virol 2023;53:1-10. 10.4167/jbv.2023.53.1.001
Grossman TH, Murphy TM, Slee AM, Lofland D, Sutcliffe JA. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother 2015;59:2567-71. 10.1128/AAC.04354-1425691636PMC4394802
Montravers P, Zappella N, Tran-Dinh A. Eravacycline for the treatment of complicated intra-abdominal infections. Expert Rev Anti Infect Ther 2019;17:851-63. 10.1080/14787210.2019.168197531622119
Zhang Y, Lin X, Bush K. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot 2016;69:600-4. 10.1038/ja.2016.7327353166
Zhao M, Lepak AJ, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model. Antimicrob Agents Chemother 2017;61:e00250-17. 10.1128/AAC.00250-1728416552PMC5487610
Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, et al. Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012;56:2559-64. 10.1128/AAC.06187-1122354310PMC3346605
Butler MS, Paterson DL. Antibiotics in the clinical pipeline in October 2019. J Antibiot 2020;73:329-64. 10.1038/s41429-020-0291-832152527PMC7223789
W, Chan J. Eravacycline injection (Xerava). Inter Med Alert 2018;40.
Scott LJ. Eravacycline: a review in complicated intra-abdominal infections. Drugs 2019;79:315-24. 10.1007/s40265-019-01067-330783960PMC6505493
Sutcliffe JA, O'brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013;57:5548-58. 10.1128/AAC.01288-1323979750PMC3811277
McCarthy MW. Clinical pharmacokinetics and pharmacodynamics of eravacycline. Clin Pharmacokinet 2019;58:1149-53. 10.1007/s40262-019-00767-z31049869
Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram- negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis 2018;91:55-62. 10.1016/j.diagmicrobio.2017.12.01329338931
Rodvold KA. Eravacycline. In: Grayson ML, Cosgrove S, Crowe S, Hope W, McCarthy J, Mills J, et al, editors. Kucers' the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs. 7th ed. Boca Raton: CRC Press; 2017. P.1273-89.
Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018;51:62-4. 10.1016/j.ijantimicag.2017.06.02228705668
Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110-6. 10.1016/j.ijantimicag.2012.09.00523127485
Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80. 10.1093/jac/dki24816040625
Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006;19:155-61. 10.1080/08998280.2006.1192815416609746PMC1426172
Thaker M, Spanogiannopoulos P, Wright GD. The tetracycline resistome. Cell Mol Life Sci 2010;67:419-31. 10.1007/s00018-009-0172-619862477
Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, et al. Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy. J Med Chem 2012;55:606-22. 10.1021/jm201467r22148555
Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, et al. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother 2014;58:2113-8. 10.1128/AAC.02036-1324468780PMC4023791
Petraitis V, Petraitiene R, Maung BBW, Khan F, Alisauskaite I, Olesky M, et al. Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits. Antimicrob Agents Chemother 2018;62:e00275-18. 10.1128/AAC.00275-1829941646PMC6125520
Newman JV, Zhou J, Izmailyan S, Tsai L. Mass balance and drug interaction potential of intravenous eravacycline administered to healthy subjects. Antimicrob Agents Chemother 2019;63:e01810-18. 10.1128/AAC.01810-1830559132PMC6395926
Medicines Agency. Xerava (Eravacycline): summary of product characteristics. 2018.
Eckburg PB, Skarinsky D, Das A, Ellis-Grosse EJ. Phenotypic antibiotic resistance in ZEUS: a multi-center, randomized, double-blind phase 2/3 study of ZTI-01 vs. piperacillin-tazobactam (P-T) in the treatment of patients with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP). Open Forum Infect Dis 2017;4:S522. 10.1093/ofid/ofx163.1360
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10. 10.1086/5162849455502
Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 2019;69:S565-75. 10.1093/cid/ciz83031724043PMC6853760
Thabit AK, Monogue ML, Nicolau DP. Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo. Antimicrob Agents Chemother 2016;60:5072-5. 10.1128/AAC.00240-1627353264PMC4958217
Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T, Olesky M, et al. In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, including multidrug- resistant (MDR) isolates, over a 3-year period (2013-2015). Open Forum Infect Dis 2016;3:1825. 10.1093/ofid/ofw172.1373
Morrissey I, Olesky M, Hawser S, Lob SH, Karlowsky JA, Corey GR, et al. In vitro activity of eravacycline against Gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob Agents Chemother 2020;64:e01699-19. 10.1128/AAC.01699-1931843999PMC7038303
Bassetti M, Melchio M, Giacobbe DR. Delafloxacin for the treatment of adult patients with community-acquired bacterial pneumonia. Expert Rev Anti Infect Ther 2022;20:649-56. 10.1080/14787210.2021.202009834913817
Chahine EB, Dougherty JA, Thornby KA, Guirguis EH. Antibiotic approvals in the last decade: are we keeping up with resistance? Ann Pharmacother 2022;56:441-62. 10.1177/1060028021103139034259076
Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial. JAMA Surg 2017;152:224-32. 10.1001/jamasurg.2016.423727851857
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 2014;58:1847-54. 10.1128/AAC.01614-1324342651PMC4023720
Nguyen F, Starosta AL, Arenz S, Sohmen D, Dönhöfer A, Wilson DN. Tetracycline antibiotics and resistance mechanisms. Biol Chem 2014;395:559-75. 10.1515/hsz-2013-029224497223
Wen Z, Shang Y, Xu G, Pu Z, Lin Z, Bai B, et al. Mechanism of eravacycline resistance in clinical Enterococcus faecalis isolates from China. Front Microbiol 2020;11:916. 10.3389/fmicb.2020.0091632523563PMC7261854
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother 2015;59:1802-5. 10.1128/AAC.04809-1425534744PMC4325809
Clark JA, Kulengowski B, Burgess DS. In vitro activity of eravacycline compared with tigecycline against carbapenem- resistant Enterobacteriaceae. Int J Antimicrob Agents 2020;56:106178. 10.1016/j.ijantimicag.2020.10617832980393
Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother 2018;62:e01174-18. 10.1128/AAC.01174-1830150464PMC6201080
Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis 2019;38:1787-94. 10.1007/s10096-019-03590-331175478
Bassères E, Begum K, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Miranda J, et al. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother 2020;75:2879-84. 10.1093/jac/dkaa28932719870PMC7678891
Rusu A, Buta EL. The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics 2021;13:2085. 10.3390/pharmaceutics1312208534959366PMC8707899
  • Publisher :The Korean Society for Microbiology and The Korean Society of Virology
  • Publisher(Ko) :대한미생물학회‧대한바이러스학회
  • Volume : 54
  • No :1
  • Pages :1-11
  • Received Date : 2024-01-02
  • Revised Date : 2024-03-21
  • Accepted Date : 2024-03-27